UK Suspends Tavneos Use Amid Unreliable Trial Data

Britain's Medicines and Healthcare products Regulatory Agency (MHRA) has suspended the use of Amgen's rare-disease drug Tavneos for new patients due to unreliable data from its main trial.

Tavneos, also known as Avacopan Vifor, is used in combination with other medications to treat severe autoimmune diseases that cause inflammation in small blood vessels and can damage the kidneys and lungs.

The MHRA plans to revoke UK approval for the drug on March 1, 2027. Patients currently taking Tavneos can continue treatment for six months while their doctors evaluate alternative options.

Amgen acquired ChemoCentryx, which developed Tavneos, for $3.7 billion in 2022. Amgen holds U.S. rights to the drug, while CSL Vifor markets it in selected countries outside the U.S., including Britain.